Calithera Biosciences (CALA)

Overall impact
B (67)

Commentary

Calithera Biosciences is a strong overall performer. With a 'B' rating of 67.3 for overall impact (77th percentile compared to all companies), Calithera Biosciences ranks 317th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 313 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 265 others. On top material causes for Calithera Biosciences's industry (Pharmaceuticals & Biotech), Calithera Biosciences performs well in Child and Maternal Health (84.4 score), Access to Affordable Healthcare (84.7), Improved Mental Health (95.7) and 3 other causes where it received an 'A' score and performs poorly in Disaster Readiness and Effective Aid (34.2 score), Reduced Green House Gas Emissions (28.1) and Humane Treatment of Animals (18.3).
Impact
Cause CALA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
8
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
CALA
Description
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Material causes
Ethos considers the following causes material for Calithera Biosciences, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.